JAK1 Inhibitor Safe, Effective for Patients With Moderate-to-Severe HS

Study findings published in the British Journal of Dermatology showed that Janus kinase 1 (JAK1) inhibitor INCB054707 displayed favorable safety and efficacy when used as treatment for patients with moderate-to-severe hidradenitis suppurativa (HS).

The researchers also examined the tolerability of INCB054707, and evaluated efficacy measures including HS Clinical Response (HiSCR).

Data were collected from 2 multi-center phase 2 trials of the JAK1 inhibitor in patients with moderate-to-severe HS aged 18 to 75 years. Lesions included were in anatomic locations (≥2) and had a total abscess and inflammatory nodule count (≥3). In trial 1, a total of 10 patients received open-label INCB054707 15 mg once daily, and in study 2, a total of 35 patients were randomized to receive 30 mg, 60 mg, or 90 mg INCB054707 or placebo for 8 weeks.

Roughly 70% of patients in study 1 and 80% of patients in study 2 receiving INCB054707 experienced treatment-emergent adverse events (TEAEs), and about 30% and 40% of patients had ≥1 treatment-related TEAEs, respectively. Per the evaluation, 3 patients in study 1 and 17 patients in study 2 achieved HiSCR at week 8 versus 4 patients receiving placebo in Study 2.

“INCB054707 was well tolerated, with responses observed in patients with moderate-to-severe HS. Safety and efficacy findings from these studies demonstrate proof of concept for JAK1 inhibition in HS,” the investigators concluded.

Reference
Alavi A, Hamzavi I, Brown K, et al. Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase 2 studies. Br J Dermatol. Published online January 2, 2022. doi:10.1111/bjd.20969